A passion to help patients and our curiosity to find new ways to treat disease drive our approach to strategic partnerships, with companies who are at the forefront of innovation in drug development.
The ground-breaking work undertaken by teams of research scientists to discover new drugs is only the start of a long and complex journey. It can take years to turn that work into treatments that reach patients.
As a scientist, it is deeply rewarding to use our experience to bring innovative treatments to patients, often in disease areas where there is high unmet need
Unlocking the potential of scientific discovery
At Mundipharma, we have experience in late-phase development and in leading global, multi-centre clinical trials in a specialty care setting.
In addition, we have a track record of successful marketing authorisations, and capabilities in commercial, manufacturing and supply. With a global reach across 120 countries, we work collaboratively to enable patients to benefit from our partners’ innovation.
Partnerships to bring innovative treatments for challenging health conditions
We are proud to work with many partners to bring innovative medicines to help treat some of the world’s most challenging health conditions.
According to the World Health Organization, asthma is estimated to affect more than 339 million people globally.1 flutiform® (fluticasone propionate/formoterol fumarate), a combination steroid and long-acting beta agonist therapy for the treatment of asthma is a product that Mundipharma has licensed from, and jointly developed with our partner Vectura, a specialist inhalation contract development and manufacturing organisation. Together, we have built a global business providing access to this therapy in over 60 countries, with future launches planned.
1. World Health Organization, https://www.who.int/news-room/fact-sheets/detail/asthma Last accessed 15 March 2021
In 2019, around 59 million people in Europe were living with diabetes, and this number is expected to rise to over 65 million by 2030. The majority have type 2 diabetes. In 2016, we entered into a partnership with Janssen, to promote and distribute Invokana® (canagliflozin) and Vokanamet® (canagliflozin/metformin) in the UK, and this was soon expanded across multiple countries in Europe.
Mundipharma is working with Janssen to provide access to these important treatments, to help reduce the burden of diabetes on patients and on healthcare systems around the world.
1. International Diabetes Federation, Diabetes Atlas https://diabetesatlas.org/data/en/region/3/eur.html. Last accessed 15 March 2021
The use of Mundipharma biosimilars has resulted in estimated savings of €1 billion to European healthcare systems since their launch.1 Biosimilars play an increasingly important role in providing cost-effective treatment options that enable broad access to effective therapies. We are committed to improving access to healthcare and to bringing new treatments to market at an affordable cost to providers. In the past six years, we have launched several Celltrion biosimilar monoclonal antibodies and Pelmeg, a biosimilar developed by Mundipharma:
In 2017, we launched Truxima®▼ (rituximab).2
In 2018, we launched Herzuma®▼ (trastuzumab).3
In 2019, we launched Pelmeg®▼ (pegfilgrastim).4
These medicines are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.yellowcard.mhra.gov.uk for how to report side effects.
- Data-on-File. MBL/Biosimilars-001. January 2020.
- Mundipharma to launch Truxima® (rituximab), the first biosimilar monoclonal antibody for the treatment of cancer, in seven European markets. Press release. Mundipharma. https://www.mundipharma.com/wp-content/uploads/2017/09/170222_Truxima-Launch-Release.pdf (Accessed March 2021).
- Herzuma® (trastuzumab), a biosimilar for the treatment of breast cancer, now available in Europe. Press release. Mundipharma. https://www.mundipharma.com/wp-content/uploads/2018/05/001-Herzuma-EU-availability-release-02052018.pdf (Accessed March 2021).
- Mundipharma launches Pelmeg® (pegfilgrastim), biosimilar in Europe. Press release. Mundipharma. https://mundipharma.eu/2019/02/07/mundipharma-launches-pelmeg%E2%96%BCpegfilgrastim-biosimilar-in-europe/ (Accessed March 2021).
Pralatrexate, tradenames FOLOTYN® and DIFOLTA®, was approved by the FDA in September 2009 as the first monotherapy drug for patients with relapsed or refractory T-cell lymphoma, a rare type of blood cancer.
In 2011, we partnered with Allos Therapeutics to bring this orphan drug to markets outside of the US. We were pleased to continue this partnership with Spectrum Pharmaceuticals when they acquired Allos in 2012, and now today with Acrotech Biopharma who acquired a number of Spectrum’s products in 2019.
During this time, we have achieved marketing authorisations from more than 20 countries, including in China and Japan where we conducted Phase 3 studies, helping address unmet need in rare cancers which have a poor prognosis.
Since 2010, we have partnered with Helsinn to provide ALOXI® and AKYNZEO® as treatment options for patients experiencing chemotherapy-induced nausea and vomiting – one of the most common side effects of cancer chemotherapy. In addition, ALOXI® is indicated for post-operative nausea and vomiting. The partnership has continued to grow in strength and scope, and now extends across Australia, China, South East Asia, Middle East, Brazil, Argentina, Uruguay and Paraguay.
The power of partnership to address unmet patient need
Fungal infections are silent killers claiming the lives of more than 1.6 million people globally every year1.
Fungal disease kills three times more people than malaria.1 Patients critically ill in hospitals or with compromised immune systems are at highest risk of developing a serious fungal infection,1 but despite existing treatments these infections are sadly fatal in up to 40% of patients.2 There are also some limitations with current treatments such as drug-drug interactions, toxicities, low or variable exposure, daily intravenous administration and increasing resistance to treatment which can complicate therapy in a vulnerable population.3,4
In collaboration with Cidara Therapeutics, Inc., we are developing rezafungin, a new long-acting therapy which improves upon a clinically validated mechanism to prevent and treat serious fungal infections.5 Through this partnership we are supporting Cidara with ongoing phase 3 studies for the treatment (ReSTORE; NCT03667690) and prevention (ReSPECT; NCT04368559) of serious fungal infection. 6,7
Reference:
- Bongomin F, Gago S, Oladele RO et al. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017;3(4).
- Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015; 373:1445-1456.
- Yu Y, Albrecht K, Groll J et al. Innovative therapies for invasive fungal infections in preclinical and clinical development. Expert Opinion on Investigational Drugs 2020.
- Gintjee TJ, Donnelley MA, Thompson GR. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. J. Fungi 2020, 6, 28:
- Sofjan AK. Mitchell A, Shah DN et al. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. Journal of Global Antimicrobial Resistance 2018; 14: 58–64.
- ClinicalTrials.gov. Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE) https://clinicaltrials.gov/ct2/show/NCT03667690
- ClinicalTrials.gov. Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT). https://clinicaltrials.gov/ct2/show/NCT04368559
Dedicated Alliance Management team
At Mundipharma, we work with organisations who share our care and commitment to make a difference to patients when it matters most. Our Alliance Management team is dedicated to working with our partners to achieve the best outcome of the alliance for our organisations and for our customers and patients.
Interested in partnering with us?
We establish long-term relationships with companies who share our commitment to bring innovative treatments to patients around the world.
If you would like to talk to us in confidence about becoming a strategic partner, please contact our Business Development team.
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.